Certara to Participate in Upcoming Investor Conferences
Certara, Inc.'s (NASDAQ:CERT) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Certara Launches Phoenix Version 8.5 Drug Development Software
Here's Why Certara (CERT) Stock Underperformed in Q2
Certara (NASDAQ:CERT) May Have Issues Allocating Its Capital
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)
Express News | Certara Inc : Morgan Stanley Cuts Target Price to $16.00 From $21.00
Morgan Stanley Lowers Price Target on Certara to $16 From $21, Keeps Equalweight Rating
Certara's Mixed Financial Performance Leads to Hold Rating Amid Market Fluctuations
Q2 2024 Certara Inc Earnings Call
Certara Is Maintained at Neutral by UBS
Express News | Baird Maintains Neutral on Certara, Lowers Price Target to $18
Certara Analyst Ratings
Certara Stock Rated 'Hold' Amid Mixed Financial Performance and Market Expectations
Express News | Certara Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 Financial Results
Earnings Call: Certara Reports Mixed Q2 Results, Eyes Chemaxon Acquisition
Express News | Certara Inc : UBS Cuts Target Price to $16 From $20
Bank of America Securities Reaffirms Their Buy Rating on Certara (CERT)
Barclays Maintains Certara(CERT.US) With Hold Rating, Maintains Target Price $16
Certara's Q2 Adjusted Earnings Fall, Revenue Increases; Reaffirms 2024 Guidance